Boehringer Ingelheim Corporation Release: New Long-Term Treatment Data Confirms Consistent Benefit And Safety Profile Of Pradaxa® Beyond 6 Years
INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only. Results from a new combined analysis of the pivotal Phase III RE-LY® trial and its extension study RELY-ABLE® show that, in long-term treatment, the efficacy and safety profiles of both doses of Pradaxa® (dabigatran etexilate, 150mg bid and 110mg bid) remain consistent with the results seen in the 18,000 patient-strong RE-LY® registration trial.1,2,3 The new data were presented during the American Heart Association’s Scientific Sessions 2013.